Case report: Avacopan-induced severe liver injury with prolonged jaundice and lipoprotein X-induced dyslipidemia

Affiliations

¹ Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan.
² Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.

Yoshiyuki Kioi et al. Int J Rheum Dis. 2024 Nov.

. 2024 Nov;27(11):e15400.

doi: 10.1111/1756-185X.15400.

¹ Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan.
² Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.

No abstract available

References

1. Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA‐associated Vasculitis. N Engl J Med. 2021;384:599‐609.
1. Yamaguchi S, Yamazaki M, Kido T, et al. A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan. Rheumatology. 2024;63:e120‐e122.
1. Kojima K, Fukui S, Tanigawa M, et al. Severe prolonged liver abnormality with jaundice during treatment for granulomatosis with polyangiitis with rituximab and avacopan. Rheumatology. 2024;63:e101‐e103.
1. Shirota S, Shirai T, Mori K, et al. Comment on: a case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan. Rheumatology. 2024;63:e149‐e150.
1. Nishino T, Tomori S, Haruyama M, Takahashi K, Mimaki M. A case of rapid avacopan‐induced liver injury in pediatric granulomatosis with polyangiitis. Pediatr Nephrol. 2024;39:2919‐2922. https://doi‐org.osaka‐u.idm.oclc.org/10.1007/s00467‐024‐06376‐8